Clinical Trials

Inclusion Criteria:

• 18 years of age.
• Suspected or tissue proven lung tumor and/or malignant peripheral/hilar lymph nodes.
• Nodule size in CT between 8mm and 30 mm (largest dimension).
• Ability to understand and willingness to sign a written informed consent and HIPAA consent document.

Exclusion Criteria:

• Inability or non-willingness to provide informed consent.
• Inability to comply with the study protocol.
• Patients with known allergy for fluorescein or risk factors for an allergic reaction.
• Use of beta-blocker within 24 hours before start of the bronchoscopic procedure.
• Possible pregnant or lactating women.
• Known allergy to fluorescein.
• Patients with hemodynamic instability. 
• Patients with refractory hypoxemia. 
• Patients with therapeutic anticoagulant that cannot be held for an appropriate interval prior to the procedure.
• Patients who are unable to tolerate general anesthesia according to the anesthesiologist.
• Patient undergoing chemotherapy.                            
• Pregnant or breast feeding.

Intra-operative Exclusion/Stopping Criteria:

• The lesions are unable to be localized/confirmed by bronchoscopy.
• The procedure will be terminated if the patient develops a significant procedural complication as determined by the treating physician.
• The procedure will be terminated if the patient develops hemodynamic instability as determined by the treating physician.

Eligibility last updated 8/16/21.  Questions regarding updates should be directed to the study team contact.